A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer

Maintenance treatment can extend patient survival and improve patient quality of life. Bevacizumab alone or capecitabine combined with bevacizumab as a maintenance treatment have been widely used in clinical practice. In contrast, there are little datas of cetuximab as a maintenance treatment. The purpose of this study is to evaluate efficacy and safety of Raltitrexed plus Cetuximab as the maintenance treatment, and to provide a new choice for RAS wild-type colorectal cancer patients after advanced first-line chemotherapy.维持治疗（Maintenance treatment）可延长患者生存期并改善其生活质量。贝伐珠单抗（Bevacizumab）单药或卡培他滨（capecitabine）联合贝伐珠单抗作为维持治疗已在临床广泛应用。与之相对，西妥昔单抗（cetuximab）作为维持治疗的相关数据仍较为匮乏。本研究旨在评估雷替曲塞（Raltitrexed）联合西妥昔单抗作为维持治疗的疗效与安全性，为一线晚期化疗后的RAS野生型结直肠癌患者提供全新的治疗选择。